Tagged with BMS,

Colombia Sandra Ramirez, General Manager of Bristol-Myers Squibb Colombia & Mexico, reveals valuable insights into the long-standing presence of BMS in Colombia, marked by a continuous dedication to increase access to medicine, the gradual development of their immuno-oncology pipeline and the creation of an inclusive culture formed by satisfied employees. Ms.…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…

France Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this field, with a number of companies, institutes and hospitals pioneering new forms of treatment and adapting policy to fit the…

Ireland Noel Heaney, general manager of BMS Biologics Ireland, provides an overview of BMS in Ireland, its exciting new USD 900 million biologics facility in Cruiserath, their innovative HR programs and his five-year-vision for BMS Biologics in Ireland. BMS has a strong heritage in Ireland dating back to 1964 when it…

Pharma The GM of France for Bristol-Myers Squibb (BMS) discusses becoming a “diversified biopharma company”, their commitment to remaining a model of excellence for other affiliates, and his personal philosophy of leadership, moulded by two decades of international experience. You started off your term with a restructuring plan for the French…

Pharma Automation and consolidation have affected pharmaceutical companies worldwide, and Puerto Rico is no exception. The island has benefited from the trend towards lower volume, higher value products which often use the smaller plants Puerto Rico offers. Some companies, like Merck, are transforming their sites from pure manufacturing to commercialization. These trends point to…

BMS The country manager of a leading specialty care bio-business reveals how the economic and geo-social fundamentals in Romania are highly attractive from an innovative pharmaceutical producer standpoint. He speaks about how to navigate the complex regulatory landscape and the potential opportunity for preventative care to make the nation’s healthcare system…